Therapy with JAK2 inhibitors for myeloproliferative neoplasms.

@article{Santos2012TherapyWJ,
  title={Therapy with JAK2 inhibitors for myeloproliferative neoplasms.},
  author={F{\'a}bio Pires de Souza Santos and Srdan Verstovsek},
  journal={Hematology/oncology clinics of North America},
  year={2012},
  volume={26 5},
  pages={1083-99}
}
The development of JAK2 inhibitors followed the discovery of activating mutation of JAK2 (JAK2V617F) in patients with classic Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPN). It is now known that mutations activating the JAK-STAT pathway are ubiquitous in Ph-negative MPN, and that the deregulated JAK-STAT pathway plays a central role in the pathogenesis of these disorders. JAK2 inhibitors thus are effective in patients both with and without the JAK2V617F mutation. This… CONTINUE READING
Highly Cited
This paper has 26 citations. REVIEW CITATIONS

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
6 Extracted Citations
82 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 82 references

An expanded multicenter phase I/II study of CYT387, a JAK- 1/2 inhibitor for the treatment of myelofibrosis [abstract

  • A Pardanani, J Gotlib, V Gupta
  • Blood
  • 2011
Highly Influential
5 Excerpts

Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: survival advantage of ruxolitinib therapy [abstracts

  • S Verstovsek, HM Kantarjian, Z Estrov
  • Blood
  • 2011
Highly Influential
5 Excerpts

Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) [abstract

  • S Verstovsek, RA Mesa, SK Rhoades
  • Blood
  • 2011
Highly Influential
4 Excerpts

Durable responses with the JAK1/ JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU) [abstract

  • S Verstovsek, F Passamonti, A Rambaldi
  • Blood
  • 2010
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…